2012•Clinical Lymphoma Myeloma & LeukemiaRequires access

Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms

Jonathan R. Fromm, Julie A. McEarchern, Dana A. Kennedy, Anju Thomas, Andrei R. Shustov, Ajay K. Gopal

Open publisher page 34 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 34 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Brentuximab vedotin, CD30, Antibody-drug conjugate, Medicine, Anaplastic large-cell lymphoma, Cancer research, Internalization, Antibody

Back to paper search Browse research topics Original source

Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms — Research Paper | ScholarLens